Strategic Collaborations, Certified Solutions, Financial Results, Recognitions, and Commencement of Laboratory Operations - Analyst Notes on Quest Diagnostics, Agilent, Nordion, ICON and WuXi PharmaTech

NEW YORK, June 5, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Quest Diagnostics Inc. (NYSE: DGX), Agilent Technologies Inc. (NYSE: A), Nordion Inc. (NYSE: NDZ), ICON plc (NASDAQ: ICLR) and WuXi PharmaTech (Cayman) Inc. (NYSE: WX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3397-100free.

--
Quest Diagnostics Inc. Analyst Notes
On June 1, 2014, Quest Diagnostics (Quest Diagnostics) reported its partnership with Memorial Sloan Kettering Cancer Center (MSK), the world's oldest and largest private cancer center to utilize MSK's clinical and research insights into gene mutations associated with solid tumors. The primary objective of the collaborations is to use molecular laboratory testing to improve physicians' ability to treat patients with a variety of solid tumor cancers by giving them a better understanding of the genomic underpinnings of their patients' illnesses. "We are excited to offer oncologists and patients everywhere unprecedented access to Memorial Sloan Kettering Cancer Center's exceptional knowledge of the role of gene mutations in solid tumors and the therapies most effective in treating them," said Steve H. Rusckowski, President and CEO of Quest Diagnostics. "By combining our broad market reach, which covers half the practicing physicians and hospitals in the United States, with MSK's deep experience in cancer care and molecular science, we hope to illuminate the best possible cancer treatment options for patients across the country." The full analyst notes on Quest Diagnostics are available to download free of charge at:

http://www.analystsreview.com/Jun-05-2014/DGX/report.pdf

--
Agilent Technologies Inc. Analyst Notes
On May 30, 2014, Agilent Technologies Inc. (Agilent) announced that Simplay Labs has officially selected Agilent's HDMI 2.0 6G test solution following the HDMI Forum's certification of it as an official compliance test tool. The Company's solution provides the widest coverage for HDMI physical layer compliance test. "We're glad to be working with Simplay Labs, delivering the 6G testing solution," said Stefan Friebe, HDMI program lead for Agilent. "This solution will help Simplay Labs' HDMI ATCs do faster compliance testing and development for many R&D customers." The full analyst notes on Agilent are available to download free of charge at:

http://www.analystsreview.com/Jun-05-2014/A/report.pdf

--
Nordion Inc. Analyst Notes
On June 2, 2014, Nordion Inc. (Nordion) reported its Q2 FY 2014 (period ended April 30, 2014) financial results with revenues of $74.7 million, up 33.2% YoY. GAAP net income for the quarter totaled $6.7 million compared to net income of $0.7 million in Q2 FY 2013. GAAP diluted EPS were $0.11 compared to $0.01 in Q2 FY 2013. "Nordion delivered strong results in its second quarter, in line with our expectations," said Mr. Steve West, CEO, Nordion "We continue to focus and execute on opportunities in both our Sterilization Technologies and Medical Isotopes businesses." The full analyst notes on Nordion are available to download free of charge at:

http://www.analystsreview.com/Jun-05-2014/NDZ/report.pdf

--
ICON plc Analyst Notes
On May 15, 2014, ICON plc (ICON) announced that it has received the prestigious Informatica Innovation Award for Improved Decisions. The Company informed that the award recognizes data-centric organisations that have demonstrated leadership in using Informatica solutions to drive innovation and business advantage. Tom O'Leary, ICON's Chief Information Officer, said, "We are delighted to be recognised for innovation and for helping our customers reduce the time and cost of drug development by enabling them to make more informed decisions. We are achieving market-leading innovation through the combination of our industry expertise and enabling technologies such as ICONIK, Firecrest and ADDPLAN. As a trusted partner to our customers, ICON remains committed to drive further innovation to enhance the drug development process." The full analyst notes on ICON are available to download free of charge at:

http://www.analystsreview.com/Jun-05-2014/ICLR/report.pdf

--
WuXi PharmaTech (Cayman) Inc. Analyst Notes
On May 28, 2014, WuXi PharmaTech (Cayman) Inc. (WuXi PharmaTech) announced that its manufacturing subsidiary, Syn-The-All Pharmaceutical Co., Ltd, has commenced operation of high-potency active pharmaceutical ingredient (HPAPI) laboratory in Shanghai, which adds HPAPI processing to its portfolio of services. "With the increasing use of HPAPIs in drug discovery and development, this new service augments WuXi's ability to provide highly efficient and cost-effective solutions for our partners worldwide," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. The laboratory aims to support process development and clinical-trial supply of high-potency small molecules at kilogram scale. The full analyst notes on WuXi PharmaTech are available to download free of charge at:

http://www.analystsreview.com/Jun-05-2014/WX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED